Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afuresertib plus fulvestrant for previously treated HR-positive/HER2-negative advanced or metastatic breast cancer
CTR20240665Phase 3Completed
- Sponsor
- Laekna
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of afuresertib, fulvestrant in breast cancer, sponsored by Laekna. Started May 2024; status: completed.
02
Drugs
afuresertibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20240665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240665.